A vaccine for preventing hemorrhagic pneumonia in musk deer and its preparation method
By developing a vaccine containing live animal Bergerella ulcerans bacterial solution and outer membrane lipoprotein, the technical shortcomings in the prevention and control of hemorrhagic pneumonia in musk deer have been addressed, achieving safe and efficient immune protection, reducing antibiotic use and the risk of drug resistance, and meeting the needs of musk deer farming.
Patent Information
- Application Number
- CN202611180550.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-05
- Publication Date
- 2026-11-10
AI Technical Summary
There is a lack of effective vaccines for hemorrhagic pneumonia in musk deer, especially vaccines against Bergenia ulcerans, which leads to poor prevention and control. In addition, existing vaccines are difficult to administer and have many adverse reactions, which cannot meet the needs of musk deer farming.
Develop a vaccine containing inactivated animal Bergenia ulcerans bacterial solution and white oil adjuvant, combining animal Bergenia ulcerans outer membrane lipoprotein with white oil adjuvant, administer immunization via intramuscular injection, and establish experimental animal models to evaluate the immunoprotective effect.
It achieves safe and efficient immune protection, reduces the amount of antibiotics used and the risk of drug resistance, and provides a new technical route for the prevention and control of hemorrhagic pneumonia in forest musk deer, with prospects for industrial application.
Smart Images

Figure CN123059147A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of veterinary biological products technology, and in particular to a vaccine for the prevention of hemorrhagic pneumonia in forest musk deer and its preparation method. Background Technology
[0002] As a Class I protected wild animal in China, artificial breeding is a crucial means of species conservation and resource propagation for the forest musk deer. Acute hemorrhagic pneumonia is a core disease with an extremely high mortality rate in forest musk deer breeding, severely hindering the healthy development of the artificial breeding industry and the advancement of species conservation efforts. Current research indicates that the pathogen of this disease is complex, with multiple pathogens such as Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa being common causes. Due to the species protection level of the forest musk deer, systematic animal reintroduction experiments cannot be conducted, resulting in a long-term lag in etiological research on this disease, and the pathogenic mechanism and pathogenesis remain not fully understood.
[0003] Extensive clinical data confirms a strong correlation between *Bergesia ulcerans* and the pathogenesis of acute hemorrhagic pneumonia in musk deer, with *Bergesia ulcerans* being a key pathogen that plays a central role in the disease's development. However, current prevention and control technologies for hemorrhagic pneumonia in musk deer have significant shortcomings, particularly in vaccine development, which has progressed slowly. There is currently no commercially available vaccine suitable for hemorrhagic pneumonia in musk deer; vaccines against the relevant pathogens are only at the laboratory testing stage. Furthermore, specific research on *Bergesia ulcerans* is extremely scarce, lacking both a corresponding reference research system and commercially available vaccine products, representing a research vacuum.
[0004] Currently, the prevention and control methods for hemorrhagic pneumonia in musk deer are extremely limited, with clinical treatment mainly relying on antibiotics. However, long-term and repeated use of antibiotics has led to a continuous increase in drug resistance in pathogens, resulting in a decline in the effectiveness of prevention and control year by year. Furthermore, there are potential risks such as drug residues and the spread of drug-resistant bacteria. Overall, existing research focuses primarily on basic aspects such as pathogen detection and identification, and pathogen characterization analysis, while research on immunoprophylaxis techniques and the development of dedicated vaccines against *Bergeia ulcerans* in animals is severely lacking.
[0005] Bergenia ulcerans is a rare pathogen, presenting challenges in isolation and culture, as well as a lack of research on its biological characteristics and an incomplete basic research system. Furthermore, the absence of suitable animal models hinders the effective verification of the strain's pathogenicity, vaccine efficacy, and protective effects, further restricting vaccine development. Additionally, existing pathogen vaccines generally use oil-based Freund's adjuvant, but this adjuvant system is poorly suited for musk deer farming: musk deer are small, highly wild, and sensitive to stress, making vaccine injection difficult. Moreover, the oil-based adjuvant easily induces adverse reactions such as local inflammation, swelling, and necrosis, significantly limiting its application and failing to meet clinical prevention and control needs.
[0006] Therefore, there are currently no safe and effective immunization measures to prevent and control Burke's ulcer infection in musk deer, and existing vaccine systems and prevention and control programs are not suitable for the actual scenarios of musk deer farming. Therefore, developing a targeted, safe, and suitable Burke's ulcer vaccine for animals that is compatible with the physiological characteristics and farming models of musk deer is of significant practical and scientific value for filling the technological gap in the industry, effectively preventing and controlling acute hemorrhagic pneumonia in musk deer, reducing mortality rates in farming, and ensuring the sustainable development of musk deer species conservation and the artificial breeding industry. Summary of the Invention
[0007] The purpose of this invention is to address the lack of vaccines against Bergenia ulcerans in existing technologies, reduce antibiotic usage and the risk of drug resistance, establish a technical system for inactivated and protein vaccines against Bergenia ulcerans in animals, induce the body to produce high levels of specific antibodies, provide a new technical route for the prevention and control of hemorrhagic pneumonia in musk deer, and have the potential for large-scale industrial development and application.
[0008] To achieve the above objectives, in a first aspect, the present invention provides a vaccine for preventing hemorrhagic pneumonia in musk deer, the vaccine comprising inactivated *Bergesia ulcerans* bacterial suspension and white oil adjuvant or *Bergesia ulcerans* outer membrane lipoprotein and white oil adjuvant; wherein the volume ratio of inactivated *Bergesia ulcerans* bacterial suspension or *Bergesia ulcerans* outer membrane lipoprotein to white oil adjuvant is 1:1; Bergey's bacterium for animal ulcers is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 59021, on August 3, 2026, at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. It is classified and named as follows: Bergeyella zoohelcum .
[0009] Furthermore, before inactivation, the viable count of *Bergesia ulcerans* bacterial suspension was 1 × 10⁻⁶. 10 CFU / mL.
[0010] Furthermore, the sequence of the outer membrane lipoprotein of *Bergeia ulcerans* is shown in SEQ ID NO.1.
[0011] Secondly, the present invention provides a method for preparing a vaccine to prevent hemorrhagic pneumonia in musk deer, comprising the following steps: mixing an equal volume of inactivated animal ulcer bacteria solution or animal ulcer outer membrane lipoprotein with white oil adjuvant to obtain a vaccine.
[0012] Furthermore, the method for preparing the inactivated Bergenia ulcera bacterial suspension is as follows: Bergerella ulcerans was inoculated onto brain heart extract agar medium and cultured at 37°C for 18-24 hours. Single colonies were picked and inoculated into brain heart extract broth and cultured at 37°C with shaking for 18-24 hours to obtain primary seed culture. The primary seed culture was then inoculated into brain heart extract broth and cultured at 37°C with shaking until the logarithmic growth phase. The bacterial culture was collected. The collected bacterial culture was centrifuged at 8000 rpm for 10 minutes, the supernatant was discarded, and the precipitate was resuspended in PBS buffer. Formaldehyde solution was added to the bacterial culture, and the culture was inactivated at 37°C for 48 hours to obtain inactivated Bergerella ulcerans bacterial culture.
[0013] Furthermore, the inoculation ratio of the primary seed solution is 1:100; the OD during the logarithmic growth phase... 600 The value was 0.6-0.8; the bacterial concentration was adjusted to 1×10⁻⁶ after resuspending in PBS buffer. 10 CFU / mL.
[0014] Further, the preparation method of the animal ulcer Burger's outer membrane lipoprotein is as follows: the encoding gene of animal ulcer Burger's outer membrane lipoprotein is inserted into the multiple cloning site of the pCold-TF prokaryotic expression plasmid, and the pCold-TF plasmid is used as a vector to express and purify the protein using an Escherichia coli expression system to obtain animal ulcer Burger's outer membrane lipoprotein; wherein, the encoding gene of animal ulcer Burger's outer membrane lipoprotein has the NCBI accession number WP_125151438.1.
[0015] Thirdly, the present invention provides the use of a vaccine for preventing hemorrhagic pneumonia in musk deer in the preparation of products for preventing hemorrhagic pneumonia in musk deer or infection with Bergerella ulcerativeolae in animals.
[0016] Furthermore, the application method is as follows: 1) Conduct a health check on the musk deer before immunization to ensure that the animals are in good health; 2) Immunization dosage: 1-2 mL of vaccine should be injected intramuscularly into each musk deer; 3) Immune site: Intramuscular injection in the hind limb; 4) Immunization schedule: The second immunization is given 2 weeks after the first immunization, and the third immunization is given 2 weeks later; 5) Observe the mental state, appetite, and body temperature of the musk deer after immunization.
[0017] Fourthly, this invention provides a method for constructing an experimental animal infection model of *Bergeia ulcerans*, using 1×102 10 Healthy guinea pigs were challenged with CFU / mL of Bergenia ulcerans bacterial suspension, resulting in lung lesions and positive PCR tests. This model was used to evaluate the immunoprotective effect of the aforementioned vaccine.
[0018] The advantages and positive effects of the vaccine for preventing hemorrhagic pneumonia in musk deer and its preparation method described in this invention are as follows: 1) The first technical system for inactivated and protein vaccines against Bergenia ulcers in animals was established; 2) Successfully solved the problem of the lack of vaccines against this pathogen in existing technologies; 3) Inactivated vaccines have high safety and no risk of live bacteria reversion; 4) It can induce the body to produce high levels of specific antibodies; 5) It has a significant immunoprotective effect in guinea pig animal models; 6) Reduce antibiotic usage and the risk of drug resistance; 7) To provide a new technical approach for the prevention and control of hemorrhagic pneumonia in musk deer; 8) It has value for industrialization and the development of veterinary biological products.
[0019] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. Attached Figure Description
[0020] Figure 1 This is an SDS-PAGE electrophoresis image of the recombinant OLP protein purified by affinity chromatography in Example 1 of this invention; Figure 2 This is a comparative diagram of lung lesions in guinea pigs in Example 2 of the present invention, where a is the TC positive challenge group; b is the BC blank control group; and c is the NC saline negative control group. Figure 3 This is a 400× control image of guinea pig lung pathological sections observed in Example 2 of the present invention, where a is the TC positive challenge group; b is the BC blank control group; and c is the NC saline negative control group. Figure 4 The image shows the lungs of guinea pigs after immunization with the vaccine in Example 3 of this invention. In this image, a is the animal berghei ulcer outer membrane lipoprotein OLP vaccine, and b is the animal berghei ulcer inactivated vaccine. Figure 5 This is a graph showing the antibody titer in guinea pig serum detected by the ELISA method in Example 4 of the present invention. In the graph, a represents the animal immunization group of Bergenia ulcerata outer membrane lipoprotein OLP vaccine, and b represents the animal immunization group of Bergenia ulcerata inactivated vaccine. Figure 6 This is a necropsy comparison image of the lungs of guinea pigs used in Example 4 of the present invention for determining the minimum lethal dose. In the image, a is the negative control group (0.4 mL physiological saline), and b is the control group (0.4 mL 1×10⁻⁶). 10 CFU / mL bacterial suspension treatment group, c = 0.4mL 1×10 9 CFU / mL bacterial suspension treatment group, d = 0.4mL 1×10 8CFU / mL bacterial suspension treatment group; Figure 7 This is a comparative diagram of lung lesions in guinea pigs after challenge in Example 4 of the present invention, where a is the PC group, b is the TC1 group, c is the TC2 group, and d is the NC group. Figure 8 The image shows a 400× comparison of pathological sections of guinea pig lungs after challenge in Example 4 of this invention. In the comparison, a represents the PC group, b represents the TC1 group, c represents the TC2 group, and d represents the NC group.
[0021] Information on the preservation of biological materials Bergey's bacterium for animal ulcers is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 59021, on August 3, 2026, at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. It is classified and named as follows: Bergeyella zoohelcum . Detailed Implementation
[0022] The technical solution of the present invention will be further described below with reference to the accompanying drawings and embodiments.
[0023] Unless otherwise defined, the technical or scientific terms used in this invention shall have the ordinary meaning as understood by one of ordinary skill in the art to which this invention pertains.
[0024] Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without inventive effort are within the scope of protection of this invention. Experimental methods in the following embodiments that do not specify specific conditions are generally determined according to national standards. Experimental instruments, equipment, and reagents in the following embodiments that do not specify their sources are all commercially available materials.
[0025] Unless otherwise defined or stated, all technical and scientific terms used in this invention have the same meaning as those skilled in the art. Furthermore, any methods and materials similar to or equivalent to those described herein may be applied to the methods of this invention.
[0026] The outer membrane lipoprotein sequence of *Bergeia ulcerans* in this application (SEQ ID NO.1) is referenced in NCBI RefSeq (WP_125151438.1).
[0027] The sequence of the outer membrane lipoprotein removal signal peptide of Bergenia ulcerans is shown in SEQ ID NO.2.
[0028] Example 1: Preparation of the vaccine 1. Pathogen collection and isolation: Samples were collected from the lesions in the lungs of musk deer that died from hemorrhagic pneumonia and cultured on 10% defibrinated sheep blood, brain and heart extract agar to obtain pure culture strains.
[0029] 2. Pathogen identification: The bacterial morphology was observed by Gram staining, and 16S rRNA gene PCR amplification, specific primer PCR amplification, and sequencing analysis were performed to determine that the isolated strain was Bergenia ulcerans.
[0030] Bergey's bacterium for animal ulcers is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 59021, on August 3, 2026, at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. It is classified and named as follows: Bergeyella zoohelcum .
[0031] 3. Bacterial culture: Inoculate *Bergesia ulcerans* on brain heart extract agar medium and incubate at 37°C for 18-24 hours. Pick single colonies and inoculate them into brain heart extract broth. Incubate at 37°C with shaking for 18-24 hours to obtain primary seed culture.
[0032] 4. Expand cultivation: The primary seed culture was inoculated into brain and heart extract broth at a ratio of 1:100 and cultured at 37°C with shaking until the logarithmic growth phase was reached, with an OD600 value of 0.6-0.8. The bacterial culture was then collected.
[0033] 5. Bacterial solution concentration: Centrifuge the collected bacterial culture at 8000 rpm for 10 minutes, discard the supernatant, resuspend the precipitate in PBS buffer, and adjust the bacterial concentration to 1×10⁻⁶. 10 CFU / mL.
[0034] 6. Formaldehyde inactivation: Add formaldehyde solution to the bacterial culture to a final concentration of 0.4%, inactivate at 37°C for 48 hours, shaking and mixing once every 12 hours during the period.
[0035] 7. Inactivation verification: Take 100 μL of the inactivated bacterial solution and spread it on the surface of 10% defibrinated sheep blood, brain and heart extract agar medium. Incubate at 37°C for 48 hours. If no bacterial growth is observed, the inactivation is considered qualified.
[0036] 8. Adjuvant addition: Add white oil adjuvant to the inactivated bacterial solution and mix the white oil adjuvant and bacterial solution thoroughly at a 1:1 ratio to obtain the inactivated animal ulcer vaccine.
[0037] 9. Dispensing and storage: Dispense the prepared vaccine into sterile ampoules and store at 4°C for later use.
[0038] 10. Preparation of OLP purification solution: An outer membrane lipoprotein of *Bergeia ulcerans* was selected. The sequence of the outer membrane lipoprotein (OLP) of *Bergeia ulcerans* was obtained from NCBI. After removing the signal peptide, it was inserted into the multiple cloning site of the pCold-TF prokaryotic expression plasmid. The plasmid was sent to General Biotechnology Co., Ltd. for gene optimization and expression plasmid synthesis. Using the pCold-TF plasmid as a vector, it was expressed and purified in large quantities through the *E. coli* expression system. The purified protein was thoroughly mixed with white oil adjuvant at a ratio of 1:1 to obtain the *Bergeia ulcerans* protein vaccine, which was then stored at 4°C for later use.
[0039] like Figure 1 As shown, M: protein marker; 1: flow buffer; 2: first wash buffer; 3: second wash buffer; 4: third wash buffer; 5: fourth wash buffer; 6: fifth wash buffer; 7: first elution buffer; 8: second elution buffer; 9: third elution buffer; 10: fourth elution buffer; 11: fifth elution buffer; 12: protein expression lysis buffer.
[0040] SDS-PAGE results showed that a specific protein band appeared at approximately 70 kDa in the supernatant of bacterial cell lysis in lane 12, confirming successful expression of the recombinant OLP protein. The flow buffer (lane 1) contained a small amount of the target protein; impurities in the wash buffers of lanes 2-6 were continuously eluted and removed. The first elution buffer from lane 7 showed a clear target protein band with high purity, while subsequent elution buffers (lanes 8-11) contained extremely low levels of the target protein. This indicates that the affinity chromatography purification protocol can effectively separate the recombinant OLP protein, and the first elution fraction is suitable for collection for the preparation of an animal *Bergeia ulcerans* OLP protein vaccine.
[0041] Example 2: Animal safety trials of the vaccine 1. Establishment of animal infection models: Bergenia ulcerans is an opportunistic pathogen. Guinea pigs were selected for challenge experiments to observe lung lesions. Figure 2 (as shown) and observation of pathological tissue sections ( Figure 3 (as shown) Figure 2 In the text, 'a' represents the TC-positive challenge group (1×10⁻⁶). 10 (CFU / mL); b is the BC blank control group; c is the NC saline negative control group. Guinea pigs in the TC positive challenge group showed extensive lung congestion and hemorrhage; the blank control group and the saline negative control group showed no significant lung hemorrhage lesions.
[0042] Observation results of guinea pig lung histopathological tissue sections as follows Figure 3As shown, the alveolar structure in the challenge group was destroyed, accompanied by extensive hemorrhage and extensive inflammatory cell infiltration; the alveolar structures in the two control groups were intact, with no severe pathological damage. These pathological features are highly similar to those of acute hemorrhagic pneumonia in musk deer, indicating that this study successfully established an animal model of *Bergesia ulcerativealis* infection in guinea pigs. This model can be used to evaluate the effectiveness of subsequent vaccine immunization.
[0043] Example 3 Animal safety test Twelve healthy guinea pigs weighing 300–350 g were randomly divided into three groups of four each. Group A received an intramuscular injection of purified OLP solution (0.4 mL / guinea pig); Group B received an intramuscular injection of the prepared inactivated Bergenia ulcer vaccine (0.4 mL / guinea pig); and Group C served as a negative control, receiving an intramuscular injection of physiological saline (0.4 mL / guinea pig). The health status of the guinea pigs in each group was observed for seven consecutive days after immunization.
[0044] The results showed that no guinea pigs died in any group and no obvious clinical symptoms were observed. On day 7, necropsy was performed on all groups of guinea pigs, and the results were as follows: Figure 4 As shown, the lungs of guinea pigs injected with the vaccine in groups a and b were homogeneous pink, with no obvious lesions such as hemorrhage or consolidation, proving that the vaccine is safe.
[0045] Example 4: Guinea Pig Model Inactivated Vaccine Immunoprotection Experiment 1. Immunization program: Sixteen healthy guinea pigs weighing 300–350g were selected and randomly divided into four groups of four. TC1 group: OLP purified solution immunization injection group, each guinea pig was injected intramuscularly with 0.4 mL of OLP purified solution in the hind limb; TC2 group: Animal Burges ulcer inactivated vaccine immunization group, each guinea pig was injected intramuscularly with 0.4 mL of the prepared inactivated vaccine in the hind limb; NC group: negative control group. Each guinea pig was injected intramuscularly with 0.4 mL of physiological saline in its hind limb and was not challenged during the entire immunization process. PC group: positive challenge control group, each guinea pig was injected intramuscularly with 0.4 mL of physiological saline in its hind limb; Immunization was administered every two weeks for a total of three injections. Seven days after each immunization, blood was collected from all guinea pigs, and the serum was frozen and stored at -20°C for later use. After the entire immunization program was completed, groups TC1, TC2, and PC were challenged with the same dose of *Bergesia ulcerans*.
[0046] 2. Serum antibody level detection: This experiment used an indirect ELISA method to detect the specific antibody titers in the immune sera of guinea pigs in each group. Two antigens, purified OLP protein and *Bergeia ulcerans* culture medium, were used as coating materials. The optimal detection parameters were determined through experimental optimization. When using purified OLP protein as the coating antigen, the optimal coating concentration was 0.5 µg / mL, corresponding to an optimal dilution factor of 320 times in guinea pig serum. A concentration of 1×10⁻⁶ µg / mL was also used. 9 When using CFU / mL *Bergeia ulcerans* culture as the coating antigen, carbonate buffer was used for antigen dilution, and the optimal dilution factor for the bacterial culture was determined to be 1600-fold. The optimal dilution factor for guinea pig serum under this system was 2560-fold. Subsequent experiments were conducted using ELISA assays according to the optimized parameters to accurately determine the specific antibody levels in the serum of each group of guinea pigs.
[0047] ELISA test results as follows Figure 5 As shown, a represents the OLP purified solution immunization group; b represents the animal Bergenia ulcer inactivated vaccine immunization group. The results show that both immunization groups produced high levels of antibodies after completing all immunization procedures, with the formaldehyde inactivated vaccine producing higher levels of antibodies within a shorter immunization period.
[0048] 3. Minimum lethal dose determination: Sixteen healthy guinea pigs weighing 300–350 g were randomly divided into four groups of four. Each group of guinea pigs was given intranasal instillation of different concentrations of *Bergeia ulcerans* suspension for a challenge experiment. Group A: 0.4 mL physiological saline; Group B: 0.4 mL 1×10 10 CFU / mL; Group C: 0.4 mL 1×10 9 CFU / mL; Group d: 0.4 mL 1×10 8 CFU / mL.
[0049] After being challenged with the virus, the guinea pigs were kept independently for 7 days, and their clinical manifestations and survival status were observed in each group.
[0050] Experimental results are as follows Figure 6 As shown, the guinea pigs in the negative control group exhibited normal behavior and showed no abnormalities. Figure 6 In group a); all guinea pigs in group b died, and necropsy revealed extensive acute hemorrhage in their lungs. Figure 6 Groups b and c of guinea pigs did not die, but exhibited clinical symptoms such as shortness of breath, depression, and loss of appetite. They recovered after 2-3 days of rest. Autopsy revealed that their lungs were generally red and slightly swollen. Figure 6 Groups c and d guinea pigs did not die, showed no obvious clinical symptoms, and necropsy revealed no significant lesions in the lungs except for slight swelling. Figure 6(d) PCR testing of lung tissue from dead guinea pigs showed positive results in all samples. These experiments demonstrate that the minimum lethal dose of *Bergeia ulcerans* in animals is 1 × 10⁻⁶. 10 CFU / mL.
[0051] 4. Virus challenge protection test: Fourteen days after the final immunization, all guinea pigs except those in the NC group were challenged with viral infection via nasal drops. The challenge bacterial solution was a culture of *Bergeia ulcerans* at a concentration of 1×10⁻⁶. 10 CFU / mL, 0.4 mL nasal drops per guinea pig. After challenge, the experimental guinea pigs in each group were housed independently, and clinical symptoms were observed daily.
[0052] Survival statistics: PC group: All 4 guinea pigs died (within 7 days). Group TC1: All 3 guinea pigs survived; Group TC2: All 3 guinea pigs survived.
[0053] Clinical symptom observation results: After being challenged with the virus, guinea pigs in the PC group exhibited clinical symptoms such as disheveled fur, rapid breathing, lethargy, and loss of appetite. Guinea pigs in groups TC1 and TC2 only showed symptoms such as shortness of breath and loss of appetite on the first day of the virus challenge, and recovered on the second day; the symptoms in group TC2 were milder than those in group TC1.
[0054] 5. Pathological and histological observation: On day 14 post-challenge, surviving guinea pigs were euthanized for necropsy to observe lung pathological changes. Lung tissue was collected for HE staining and pathological section examination. The groups were: a) PC group (no immunization challenge); b) TC1 group (immunization challenge with OLP purified solution); c) TC2 group (challenge with inactivated Bergenia ulcerans vaccine); and d) NC group (negative control group, given only saline without challenge).
[0055] Results of guinea pig lung lesions Figure 7 As shown, PC group ( Figure 7 (a): Macroscopic examination of the lungs revealed acute hemorrhage and severe swelling; TC1 group ( Figure 7 (middle b): Mild swelling and slight hemorrhage were observed in the lungs; TC2 group ( Figure 7 (C) No obvious lesions such as hemorrhage, suppuration, or consolidation were observed in the lungs; only mild swelling was observed. (NC group) Figure 7 (d): The lungs showed no significant lesions except for slight swelling.
[0056] Pathological section results of guinea pig lungs are as follows Figure 8 As shown: PC group ( Figure 8(a) Overall inflammatory infiltration of the lungs, widening of the pulmonary interstitium; the structure of the bronchi at all levels is intact and clear, the bronchial epithelial cells are normal in morphology, the alveolar epithelial cells are degenerated and necrotic, forming cavities locally, with a small amount of serous exudate inside, the nuclei of necrotic cells are condensed and fragmented, the cytoplasm is dissolved, and purple eosinophilic granules (colonizing bacteria) are visible in local alveoli and alveolar interstitium, with a large number of lymphocytes infiltrating the pulmonary interstitium and perivascular space; TC1 group ( Figure 8 (b) The microscopic tissues of the lungs are clearly visible, the alveolar wall structure is intact, and no foreign bodies such as sloughed epithelial cells, red blood cells, bacterial clumps, or inflammatory cells are seen in the alveolar cavities. The interstitial capillaries are intact, no red blood cells have leaked out, and a large number of inflammatory cells infiltrate and thicken in the interstitium. TC2 group ( Figure 8 c): The interstitium showed obvious inflammatory cell infiltration and thickening, which was milder than that of the lungs in the TC1 group, with no other obvious abnormalities; NC group ( Figure 8 (d) The microscopic tissues of the lungs are clearly visible, the alveolar wall structure is intact, the interstitial capillaries are intact, no red blood cells are spilled out, and no inflammatory cell infiltration or thickening is seen in the interstitium.
[0057] The results of the challenge protection experiment and histopathological observation jointly proved that both the OLP purified solution and the inactivated vaccine against Burges ulcerans in animals have an immune effect on acute hemorrhagic pneumonia induced by Burges ulcerans in animals, and the inactivated vaccine against Burges ulcerans in animals has a better immune effect than the protein vaccine made from the OLP purified solution.
[0058] Example 5: Application of inactivated Bergenia ulcerans vaccine in the prevention of bacterial pneumonia in musk deer. The vaccine prepared in Example 1 was used to immunize the musk deer. The immunization steps included: (1) A health check should be performed on the musk deer before immunization to ensure that the animals are in good health; (2) Immunization dosage: 1-2 mL of vaccine was injected intramuscularly into each musk deer; (3) Immune site: Intramuscular injection in the hind limb; (4) Immunization schedule: The second immunization is given 2 weeks after the first immunization, and the third immunization is given 2 weeks after that; (5) After immunization, the mental state, appetite, body temperature and other indicators of the musk deer should be observed, and any abnormalities should be dealt with in a timely manner.
[0059] In summary, the vaccine and its preparation method for preventing hemorrhagic pneumonia in musk deer provided by this invention construct two sets of immunizing agents: an animal Bergenia ulcerans OLP protein vaccine and a whole-cell inactivated vaccine. The invention also completed a systematic experimental study encompassing bacterial identification, formulation purification, infection model construction, immunogenicity testing, and evaluation of protective efficacy against challenge. This invention addresses the lack of a vaccine specifically targeting Bergenia ulcerans in animals, reduces antibiotic usage and the risk of drug resistance, and provides a new technical approach for the prevention and control of hemorrhagic pneumonia in musk deer, possessing high scientific research value and application prospects.
[0060] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can still be made to the technical solutions of the present invention, and these modifications or equivalent substitutions cannot cause the modified technical solutions to deviate from the spirit and scope of the technical solutions of the present invention.
Claims
1. A vaccine for preventing hemorrhagic pneumonia in musk deer, characterized in that: The vaccine comprises inactivated animal ulcer bacteria solution and white oil adjuvant or animal ulcer outer membrane lipoprotein and white oil adjuvant; wherein the mixing volume ratio of inactivated animal ulcer bacteria solution or animal ulcer outer membrane lipoprotein to white oil adjuvant is 1:
1. Bergey's bacterium for animal ulcers is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 59021, on August 3, 2026, at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. It is classified and named as follows: Bergeyella zoohelcum .
2. The vaccine according to claim 1, characterized in that: Before inactivation, the viable count of *Bergesia vesicatoria* bacterial suspension in animal ulcers was 1 × 10⁻⁶. 10 CFU / mL.
3. The vaccine according to claim 1, characterized in that: The sequence of the outer membrane lipoprotein of *Bergeia ulcerans* is shown in SEQ ID NO.
1.
4. A method for preparing a vaccine for preventing hemorrhagic pneumonia of the forest musk deer according to any one of claims 1-3, characterized in that, The process includes the following steps: mixing an equal volume of inactivated *Bergesia ulcerans* bacterial solution or *Bergesia ulcerans* outer membrane lipoprotein with white oil adjuvant to obtain a vaccine.
5. The preparation method according to claim 4, characterized in that: The method for preparing the inactivated Bergenia ulcera bacterial solution is as follows: Bergerella ulcerans was inoculated onto brain heart extract agar medium and cultured at 37°C for 18-24 hours. Single colonies were picked and inoculated into brain heart extract broth and cultured at 37°C with shaking for 18-24 hours to obtain primary seed culture. The primary seed culture was then inoculated into brain heart extract broth and cultured at 37°C with shaking until the logarithmic growth phase. The bacterial culture was collected. The collected bacterial culture was centrifuged at 8000 rpm for 10 minutes, the supernatant was discarded, and the precipitate was resuspended in PBS buffer. Formaldehyde solution was added to the bacterial culture, and the culture was inactivated at 37°C for 48 hours to obtain inactivated Bergerella ulcerans bacterial culture.
6. The preparation method according to claim 5, characterized in that: The inoculation ratio of the primary seed solution was 1:100; OD during the logarithmic growth phase 600 The value was 0.6-0.8; the bacterial concentration was adjusted to 1×10⁻⁶ after resuspending in PBS buffer. 10 CFU / mL.
7. The preparation method according to claim 4, characterized in that, The preparation method of the outer membrane lipoprotein of *Bergesia ulcerans* is as follows: the encoding gene of the outer membrane lipoprotein of *Bergesia ulcerans* is inserted into the multiple cloning site of the pCold-TF prokaryotic expression plasmid, and the pCold-TF plasmid is used as a vector to express and purify the protein using an *E. coli* expression system to obtain the outer membrane lipoprotein of *Bergesia ulcerans*; wherein, the encoding gene of the outer membrane lipoprotein of *Bergesia ulcerans* has the NCBI accession number WP_125151438.
1.
8. The use of the vaccine for preventing hemorrhagic pneumonia of musk deer according to any one of claims 1-3 in the preparation of products for preventing hemorrhagic pneumonia of musk deer or Burgellella ulcerans infection in animals.
9. The application according to claim 8, characterized in that, The application method is as follows: 1) Conduct a health check on the musk deer before immunization to ensure that the animals are in good health; 2) Immunization dosage: 1-2 mL of vaccine should be injected intramuscularly into each musk deer; 3) Immune site: Intramuscular injection in the hind limb; 4) Immunization schedule: The second immunization is given 2 weeks after the first immunization, and the third immunization is given 2 weeks later; 5) Observe the mental state, appetite, and body temperature of the musk deer after immunization.
10. A method for constructing an experimental animal infection model of *Bergeia ulcerans*, characterized in that: Using 1×10 10 Healthy guinea pigs were challenged with CFU / mL of Bergenia ulcerans bacterial suspension, resulting in lung lesions and positive PCR tests. This model was used to evaluate the immunoprotective effect of the vaccine according to any one of claims 1-3.
